Truist Securities Reiterates Buy Rating on VRDN
Truist Securities maintains its buy rating on VRDN with a $38 price target, a 102.24% upside from the current price.
Key Points
- Truist Securities reiterated its buy rating on VRDN with a $38 price target on June 30, 2026.
- Truist Securities's $38 price target implies 102.24% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
- VRDN shares traded around $18.79 on Tuesday.
- FMR LLC, BlackRock, and Bellevue Group AG increased their positions in VRDN.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities has reaffirmed its buy rating on VRDN, setting a price target of $38. This reiteration, announced on June 30, 2026, reflects continued confidence in the stock's potential.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in VRDN
Several institutional investors have been active in VRDN recently. FMR LLC increased its holdings by 994,921 shares, resulting in a total of 15,379,377 shares valued at about $300.82 million, marking a 6.9% increase. BlackRock, Inc. boosted its position by 1,399,552 shares to 7,831,475 shares, worth approximately $153.18 million, a 21.8% rise. Bellevue Group AG added 2,367,617 shares, bringing its total to 6,726,144 shares valued at $131.56 million, reflecting a 54.3% increase. State Street Corp grew its stake by 1,206,325 shares, ending with 4,672,885 shares valued at $91.40 million, a 34.8% increase. Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at $81.51 million.
Viridian Therapeutics, Inc. Stock Down 18.6%
On Tuesday, VRDN shares traded around $18.79. The stock has seen significant interest from institutional investors, evidenced by recent peer activity. This indicates a robust interest in the company's potential growth.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Insider activity at VRDN has been notable. Fairmount Funds Management LLC acquired 1,176,470 shares at an average price of $17 on May 11, 2026. Additionally, several executives, including Chief Legal Officer Jennifer Tousignant, Chief Operating Officer Thomas Beetham, Chief Financial Officer Seth Harmon, and President and CEO Stephen Mahoney, sold shares on March 3, 2026, at an average price of $30.19.
Analysts Set New Price Targets
On June 30, 2026, Truist Securities maintained its buy rating on VRDN with a $38 price target. Wedbush also maintained a buy rating, setting a target of $43. Needham kept its buy rating with a $34 target. On June 29, 2026, Wells Fargo upgraded the stock to a buy with a $31 target. The consensus among analysts is a buy rating, with a mean target price reflecting confidence in VRDN's prospects.
Bottom Line
VRDN has caught the attention of analysts and institutional investors alike, with Truist Securities and others maintaining optimistic views. While the stock currently trades below analyst targets, the reiterated buy ratings suggest potential upside. Investors should note that these assessments are based on past performance and do not necessarily predict future outcomes.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.